Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma Along Potential of ctDNA Analyses to Detect Residual Disease By Ogkologos - September 22, 2025 371 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase II study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR New on NCI’s Websites for September 2020 September 2, 2020 High Tumour Mutation Burden Fails to Predict Response to Immune Checkpoint... March 17, 2021 Study Offers Insights on Health Problems among AYA Cancer Survivors August 7, 2020 Saying YES: Inspiring a Diverse Generation of Cancer Scientists October 8, 2020 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΡΟΣΤΑΤΗ Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients... FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy ctDNA-Guided Treatment Influence on Survival in Advanced NSCLC
